Pharmacogenomics-guided personalized medicine in a clinical setting: real-world data
Systematic pharmacogenetic panel testing in clinical hyperpolypharmacy patients identified at least one DGI in 46% of the patients. Of these DGIs, 19% led to a recommendation for intervention. This study demonstrates that pharmacogenetic panel testing holds the potential to optimize pharmacotherapy in clinical hyperpolypharmacy patients.
Authors
- Laura Brand (ORCID: https://orcid.org/0009-0009-9829-5647)
- Cornelis F. Vos (ORCID: https://orcid.org/0000-0001-6760-1474)
- L. L. Krens (ORCID: https://orcid.org/0000-0003-3842-9585)
- Jesse J. Swen (ORCID: https://orcid.org/0000-0002-3965-5552)
- Joris J. B. van der Vlugt
- Tessa M. Bosch (ORCID: https://orcid.org/0000-0002-9337-7784)
- Pieter W. Smit (ORCID: https://orcid.org/0000-0003-1053-3591)
- Rikje Ruiter (ORCID: https://orcid.org/0000-0002-8107-2924)
- Jiayi Liang (ORCID: https://orcid.org/0000-0001-5796-3412)
- Ismaïl Aarab
Institutions
- Leiden University Medical Center (NL)
- Parnassia Groep (NL)
- Maasstad Ziekenhuis (NL)
- Antes (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Pharmacogenetics and Genomics
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1097/fpc.0000000000000584
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00